Valuation: Strides Pharma Science Limited

Market Cap 99.08B 1.03B 900M 830M 765M 1.44B 1.47B 9.93B 3.9B 48.51B 3.86B 3.78B 167B P/E 2026
15.5x
P/E 2027 * 15.8x
Enterprise Value 99.08B 1.03B 900M 830M 765M 1.44B 1.47B 9.93B 3.9B 48.51B 3.86B 3.78B 167B EV / Sales 2026
1.78x
EV / Sales 2027 * 1.7x
Free-Float
68.07%
Yield 2026
0.53%
Yield 2027 * 0.28%
1 day+2.57%
1 week-0.36%
Current month-1.40%
1 month-2.64%
3 months+7.71%
6 months+19.68%
Current year+19.45%
1 week 1,008.5
Extreme 1008.5
1,100
1 month 1,008.5
Extreme 1008.5
1,149.4
Current year 769.6
Extreme 769.6
1,231.45
1 year 769.6
Extreme 769.6
1,231.45
3 years 412.45
Extreme 412.45
1,675.25
5 years 263.45
Extreme 263.45
1,675.25
10 years 263.45
Extreme 263.45
1,675.25
Manager TitleAgeSince
Chief Executive Officer - 2024-05-31
Director of Finance/CFO 42 2024-05-31
Chief Tech/Sci/R&D Officer - 2024-11-20
Director TitleAgeSince
Chairman 65 -
Director/Board Member 82 2017-05-17
Director/Board Member 58 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
+2.57%-0.36% - - 1.03B
-0.90%-0.15%+13.46%+79.34% 48.15B
-0.23%-1.65%+65.14%+115.81% 35.59B
-0.76%-1.44%-4.30%+37.38% 11.9B
-0.88%-0.62%+16.38%+89.65% 11.85B
+0.19%+2.87%+34.92%+127.54% 9.31B
-0.75%-0.91%+18.26%+37.23% 6.91B
-9.93%+0.35%-29.90%+14.89% 6.13B
+3.37%-0.10%+49.31%-4.38% 7.02B
-2.25%-2.08%+0.40%+218.27% 6.55B
Average -0.96%+0.06%+18.19%+79.53% 15.93B
Weighted average by Cap. -0.86%-0.42%+25.98%+86.36%

Financials

2026 2027 *
Net sales 48.28B 501M 438M 405M 373M 703M 718M 4.84B 1.9B 23.64B 1.88B 1.84B 81.45B 58.23B 605M 529M 488M 450M 848M 866M 5.83B 2.29B 28.51B 2.27B 2.22B 98.24B
Net income 5.74B 59.58M 52.1M 48.08M 44.29M 83.56M 85.37M 575M 226M 2.81B 224M 219M 9.68B 6.28B 65.2M 57M 52.61M 48.46M 91.43M 93.41M 629M 247M 3.07B 245M 239M 10.59B
Net Debt - -
Logo Strides Pharma Science Limited
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Employees
3,301
Date Price Change Volume
26-07-17 ₹1,077.90 +2.57% 14,873
26-07-16 ₹1,050.90 -1.07% 4,883
26-07-15 ₹1,062.30 -0.67% 2,890
26-07-14 ₹1,069.50 -0.50% 5,430
26-07-13 ₹1,074.85 -0.64% 3,534
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1,074.90INR
Average target price
1,338.67INR
Spread / Average Target
+24.54%

Quarterly revenue - Rate of surprise